| 1/13/2026 | CV | Market Commentary: Travere Therapeutics sinks outright, adds on hedge on FDA approval delay; Ligand down
|
| 8/14/2025 | CV | Ligand greenshoe lifts 0.75% convertibles due 2030 to $460 million
|
| 8/12/2025 | CV | Market Commentary: Denison Mines to price overnight; DigitalOcean, Upstart, Ligand, WisdomTree expand
|
| 8/12/2025 | CV | Market Commentary: Morning Commentary: DigitalOcean, Upstart, Ligand, WisdomTree convertibles expand
|
| 8/12/2025 | CV | New Issue: Ligand prices $400 million five-year convertible notes to yield 0.75%, up 32.5%
|
| 8/11/2025 | CV | Market Commentary: Convertibles primary market unleashes four deals, more in pipeline; new deals in demand
|
| 8/11/2025 | CV | Market Commentary: Morning Commentary: Convertibles primary market unleashes three deals
|
| 8/11/2025 | CV | Ligand Pharmaceuticals talks $400 million five-year convertibles at 0.75%-1.25%, up 27.5%-32.5%
|
| 2/12/2021 | CV | Market Commentary: Ligand volatile; HubSpot convertible notes soar on earnings; Twitter, Peloton improve
|
| 10/3/2019 | CV | Market Commentary: Broadcom active among mandatories; Tesla down, MercadoLibre underperforms; Ovid on tap
|
| 10/3/2019 | CV | Market Commentary: Morning Commentary: MercadoLibre convertibles underperform; Ligand, PDC Energy in trade
|
| 7/30/2019 | CV | Market Commentary: RingCentral, NXP Semiconductors, Neurocrine Biosciences, Ligand active post-earnings
|
| 1/17/2019 | CV | Market Commentary: Aurora Cannabis convertibles offering eyed; Energizer flat; Ligand sees slight rebound
|
| 1/17/2019 | CV | Market Commentary: Morning Commentary: Primary market eyes Aurora Cannabis convertible notes offering
|
| 1/16/2019 | CV | Market Commentary: Aurora convertibles on tap; Energizer expands on debut; EFII, Ligand notes bludgeoned
|
| 11/8/2018 | CV | Market Commentary: Omeros convertibles on tap; Microchip in focus; Ligand improves; Horizon Global tanks
|
| 11/8/2018 | CV | Market Commentary: Morning Commentary: Microchip convertibles in focus post-earnings; Ligand notes improve
|
| 10/18/2018 | CV | Market Commentary: Evolent Health hits the market; Aegean Marine notes eyed; Ligand, Exact Sciences active
|
| 8/15/2018 | CV | Market Commentary: Illumina on tap; market eyes New Mountain, FTI; Enphase Energy prices; Canopy jumps
|
| 5/23/2018 | CV | Market Commentary: Square, Envestnet convertibles hit the market, expand; Ligand, NRG, FireEye below par
|
| 5/23/2018 | CV | Ligand amends 0.75% convertibles due 2019 to pay cash for conversions
|
| 5/22/2018 | CV | Ligand greenshoe lifts 0.75% convertibles due 2023 to $750 million
|
| 5/21/2018 | CV | Market Commentary: Convertibles calendar builds; Envestnet, Square on tap; market eyes FireEye, NRG Energy
|
| 5/18/2018 | CV | Market Commentary: Convertible issuance heavy during week; Ligand dominates trading; AmTrust loses ground
|
| 5/18/2018 | CV | Market Commentary: Morning Commentary: New convertible notes from Ligand in focus; AmTrust down in early trading
|
| 5/18/2018 | CV | New Issue: Ligand prices $650 million five-year convertible notes to yield 0.75%, up 30%
|
| 5/17/2018 | CV | Market Commentary: Akamai’s $1 billion deal dominates market, expands on debut; Ligand eyed; WWE improves
|
| 5/17/2018 | CV | Market Commentary: Morning Commentary: Akamai’s new $1 billion deal hits the market; Ligand convertibles on tap
|
| 5/16/2018 | CV | Ligand talks $650 million five-year convertible notes to yield 0.5% to 1%, up 27.5% to 32.5%
|
| 5/16/2018 | CV | Market Commentary: Akamai eyed; Ligand on tap; New Relic, Alteryx, Prospect Capital, KKR REIT hit market
|
| 8/18/2014 | CV | Ligand greenshoe lifts 0.75% five-year convertibles to $245 million
|
| 8/13/2014 | CV | Market Commentary: Convertibles weaker; Apollo drops with add-on; Ligand, EnerNOC flattish; planned AOL eyed
|
| 8/13/2014 | CV | Market Commentary: Morning Commentary: Four new issues debut in market; Ligand, EnerNOC trading around par
|
| 8/13/2014 | CV | New Issue: Ligand sells $225 million five-year convertibles at 0.75% up 35%
|
| 8/12/2014 | CV | Market Commentary: New Aegerion flat to better amid weak shares; Nuance bonds active after earnings, call
|
| 8/12/2014 | CV | Market Commentary: Morning Commentary: New Aegerion adds despite weaker shares; planned Ligand looks cheap
|
| 8/11/2014 | CV | Market Commentary: Tesla adds on upgrade; Chiquita edges up on takeover offer; Empire State down since issue
|
| 8/11/2014 | CV | Ligand plans $225 million five-year convertibles to yield 0.5%-1%, up 32.5%-37.5%
|
| 10/14/2011 | CVPF | Ligand files $30 million shelf covering stock, debt and preferrreds
|
| 11/29/2006 | CV | Ligand 6% convertible noteholders convert ahead of call
|
| 10/30/2006 | BTCV | Ligand calls 6% convertibles
|
| 6/28/2005 | CV | Market Commentary: Lonza issue emerges; Walter better as takeover anxiety eases; Interpublic holders to get windfall payment
|
| 6/27/2005 | CV | Market Commentary: Lear eases on layoffs; airlines dive on oil spike; Weatherford watched as put nears; CV, Impax deals eyed
|
| 3/28/2005 | CV | Market Commentary: Nuveen deals surface; Ligand off on drug data; AIG buyers emerge; Delta lower amid deal mumbling
|
| 8/31/2004 | CV | Market Commentary: Six Flags higher on Gates, Redskins owner play; IMC Global rises; Albertson's off
|
| 8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
| 9/22/2003 | CV | Market Commentary: Motorola gains with stock on CEO departure; BioMarin steady after drug canceled
|
| 12/2/2002 | CV | Ligand says $20.25 million greenshoe exercised, raising convertibles to $155.25 million
|
| 11/21/2002 | CV | New Issue: Ligand $135 million convertibles yield 6%, up 22%
|
| 11/21/2002 | CV | Market Commentary: Possible Tyco mega-deal sets market abuzz, seen placing easily; AMD, Xcel deals gain sharply
|
| 11/20/2002 | CV | Market Commentary: Xcel's new deal screams higher while others edge up, languish
|
| 11/19/2002 | CV | Market Commentary: New issue terms, credits not so fantastic, but illustrate appetite
|
| 11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
| 11/13/2002 | CV | Ligand launches $135 million converts at 5.75%-6.25% yield, up 15-20%
|
| 11/13/2002 | CV | Market Commentary: Teva deal gets warm welcome in an otherwise tepid market
|
| 11/12/2002 | CV | Market Commentary: New deals provide stimulation late, after very quiet session
|
| 11/12/2002 | CV | Ligand Pharmaceuticals plans to sell $135 million of convertibles
|
